Publications by authors named "Marie-Catherine Desroches"

Photodynamic therapy (PDT) involves a non invasive treatment of small and superficial cancers using a photosensitive drug and light to kill tumoral cells. 5,10,15-meso-tri-(meta-O-beta-D-glucosyloxyphenyl)-20-phenylporphyrin [m-TPP(glu)3] is a new photosensitizer (PS) with more enhanced photocytotoxicity relative to 5,10,15,20-meso-tetra-(meta-hydroxyphenyl) chlorin [m-THPC] (Foscan). It was injected intravenously once to healthy rats at three different doses (0.

View Article and Find Full Text PDF

Glucoconjugated analogues of the meta-hydroxyphenyl porphyrin (m-THPP) and meta-hydroxyphenyl chlorin (m-THPC) has been recently synthesized. The characteristics of their triplet states have been determined with regard to their involvement in the photodynamic (PDT) efficiency. In the case of porphyrin derivatives, triplet quantum yields (Phi(T)) were ranging from 0.

View Article and Find Full Text PDF

The use of porphyrin derivatives in photodynamic therapy is of excellent prospect for the treatment of superficial or easily reachable tumors. The selection of porphyrin derivatives by tumor cells depends to a large extent of their ability to interact with the biological membrane. The evaluation of porphyrin interaction with phospholipids can thus be used as a screening method.

View Article and Find Full Text PDF

In this work, we study the physicochemical properties of some newly developed glycoconjugated photosensitizers that can be used in photodynamic therapy (PDT) of cancers: meso-tri- and tetra-(meta-O-beta-D-glucosyloxyphenyl)porphyrins and meso-, tri-, and tetra-(meta-O-beta-D-glucosyloxyphenyl)chlorins. Their properties are compared to the non-glycosylated hydroxylated parent compounds meso-tetra-(meta-hydroxyphenyl) porphyrin and meso-tetra-(meta-hydroxyphenyl)chlorin. It was found that at the ground state, all porphyrins present, independent of the substitution, have the same mean ionization constant (pKa = 2.

View Article and Find Full Text PDF